Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7HUNW)

Drug Name

Testosterone Drug Info

Synonyms

AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one

Indication

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	Approved	[1] , [2]
Hormone deficiency	5A61.1	Phase 2	[3]
Male hormonal deficiency	5A81	Investigative	[4] , [5]

Cross-matching ID

PubChem CID: 6013
ChEBI ID: CHEBI:17347
CAS Number: CAS 58-22-0
TTD Drug ID: DM7HUNW
VARIDT Drug ID: DR00108
ACDINA Drug ID: D00666

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Agonist	[4] , [5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	Highest Status	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Approved	[6]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Approved	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Approved	[8]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Androgen receptor (AR)	DTT	AR	5.955	4.868	5.902	5.567
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.009	6.988	7.442	8.135
Breast cancer resistance protein (ABCG2)	DTP	BCRP	6.732	7.513	6.326	9.277
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	8.873	2.17	2.485	3.322

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Osteoporosis

ICD Disease Classification

FB83.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.80E-02	-1.36E-01	-1.05E+00
Breast cancer resistance protein (ABCG2)	DTP	BCRP	1.91E-02	2.50E-01	1.01E+00
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	1.74E-03	-8.06E-02	-4.03E-01

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2858).
2	Emerging drugs for hypogonadism. Expert Opin Emerg Drugs. 2006 Nov;11(4):685-707.
3	ARDANA ANNOUNCES PHASE I RESULTS FOR TESTOSTERONE CREAM. FDAnews report.
4	Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
5	Complexities of androgen action. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S87-94.
6	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
7	Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008 Jun 1;14(11):3312-8.
8	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.